You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,226,934


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,226,934
Title:Anti-cancer drug
Abstract: The present invention is directed to an anti-cancer drug containing an anti-MFG-E8 antibody as an active ingredient, and to an anti-cancer drug which employs an anti-MFG-E8 antibody in combination with a cancer therapy employing an anti-cancer agent other than the anti-MFG-E8 antibody.
Inventor(s): Tahara; Hideaki (Bunkyo-ku, JP), Jinushi; Masahisa (Bunkyo-ku, JP)
Assignee: THE UNIVERSITY OF TOKYO (Tokyo, JP)
Application Number:12/995,942
Patent Claims:1. A method for treatment of cancer, comprising administering, to a patient in need thereof, an anti-MFG-E8 antibody and an anti-cancer agent other than the antibody, in combination, wherein said treatment is in the absence of administration of a tumor antigen or tumor cell, the anti-cancer agent is a tumor-cell-toxic anti-cancer agent, and the anti-MFG-E8 antibody and the tumor-cell-toxic anticancer agent are administered separately, and the anti-MFG-E8 antibody induces an immune response by binding to MFG-E8 to thereby inhibit the function of MFG-E8.

2. The method according to claim 1, wherein the anti-cancer agent is an alkylating agent, a metabolic antagonist, a microtubule inhibitor, an antibiotic anti-cancer agent, a topoisomerase inhibitor, a platinum drug, or a molecular targeted drug.

3. The method according to claim 1, wherein the anti-cancer agent is gemcitabine, 5-FU, CPT-11, etoposide, cisplatin, oxaliplatin, paclitaxel, docetaxel, dacarbazine, doxorubicin, bevacizumab, cetuximab, an anti-vascular endothelial growth factor receptor 2 inhibition antibody, or an epidermal growth factor tyrosine kinase inhibitor.

4. A method for treatment of cancer, comprising administering an anti-MFG-E8 antibody to a patient in need thereof, and a cancer therapy that does not employ the antibody, in combination, wherein said treatment is in the absence of administration of a tumor antigen or tumor cell, wherein the anti-MFG-E8 antibody induces an immune response by binding to MFG-E8 to thereby inhibit the function of MFG-E8.

5. The method of claim 4, wherein the cancer therapy is a cellular therapy.

6. The method of claim 4, wherein the cancer therapy is selected from the group consisting of radiotherapy, MR-guided focused ultrasound surgery, cryotherapy, radio frequency ablation, ethanol-injection and artery embolization, without use of a tumor antigen.

7. The method of claim 4, wherein said method is for treatment of epithelial cancer.

8. The method of claim 7, wherein said epithelial cancer is selected from the group consisting of pharyngeal cancer, laryngeal cancer, tongue cancer, lung cancer, breast cancer, esophageal cancer, stomach cancer, colon cancer, uterus cancer, ovarian cancer, liver cancer, pancreatic cancer, gallbladder cancer, kidney cancer, prostate cancer, malignant melanoma, and thyroid gland cancer.

9. The method according to claim 1, wherein the anti-MFG E8 antibody effectively potentiates the effect of the anti-cancer agent.

Details for Patent 9,226,934

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company ERBITUX cetuximab Injection 125084 02/12/2004 ⤷  Try a Trial 2028-06-02
Eli Lilly And Company ERBITUX cetuximab Injection 125084 03/28/2007 ⤷  Try a Trial 2028-06-02
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Try a Trial 2028-06-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.